Dr. Shah's clinical research interests are focused in the areas of neurofibromatosis type 1 and retinoblastoma. These studies range from translational studies to clinical trials of novel therapeutics to international consortiums studying long-term effects of therapy.
Dr. Hocking’s research aims to better understand the neurodevelopmental consequences of having survived childhood cancer or having neurofibromatosis type 1, to identify those who are most at risk for poor outcomes, and to intervene in some way in order to improve quality of life.
Dr. Belasco’s clinical and research work focuses on pediatric cancers, palliative care, neuro-oncology, neurofibromatosis, and lymphatic vascular malformations.
A rare disease hack-a-thon leads to an unusual collaboration between D3b’s bioinformaticians, including Adam Resnick, PhD, and American Airlines’ software engineers.
